1 / 6

The Status and Future of Integrative and Organ Systems Sciences October 20 – 21, 2002 Bethesda, MD

The Status and Future of Integrative and Organ Systems Sciences October 20 – 21, 2002 Bethesda, MD. Sponsored by: APS and ASPET Co-sponsors: Burroughs Wellcome Fund Merck Research Laboratories.

irina
Télécharger la présentation

The Status and Future of Integrative and Organ Systems Sciences October 20 – 21, 2002 Bethesda, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Status and Future of Integrative and Organ Systems SciencesOctober 20 – 21, 2002Bethesda, MD Sponsored by: APS and ASPET Co-sponsors: Burroughs Wellcome Fund Merck Research Laboratories

  2. Reductionist approaches are aimed at identifying molecular and cellular events, studied in purified form or in isolated systems and including genomics, proteomics, biochemistry and cell biology Integrative and Organ Systems approaches are aimed at understanding how intact biological systems function at the level of whole animals, organs and organ systems (but not in the clinic). Definitions

  3. Life Sciences Research Office(LSRO) Michael Falk Executive Director

  4. To benefit society by evaluating biological information and scientific opinion for the public and private sectors Mission

  5. James R. Bloedel Joseph R. Haywood D. Euan MacIntyre Peter C. Preusch James H. Woods Edward J. Zambraski Steering Committee

  6. Founded in 1992 – leader in the discovery of human and microbial genes 1995 “success in turning our leadership in gene discovery into leadership in the creation of proprietary pharmaceutical products” 1997 “year of change for our company, as we began to implement clinical development of our own drugs” 1998 “significant progress in its ongoing transition to a fully integrated biopharmaceutical company that discovers, develops, manufactures and markets” 2000 “genomics” found only once HGS Annual Reports

More Related